An ambispective, non-interventional, multiple cohort study to assess the management of osimertinib treatment in patients with EGFRm non-small cell lung cancer under real-world conditions in Spain
Non-small Cell Lung Cancer
18 Years - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Aug 2023 by AstraZeneca
No locations available
Patients diagnosed with locally advanced or metastatic NSCLC with activating EGFR mutations that received first line treatment with osimertinib (FLAURA regimen).
Patients with stage IB-IIIA NSCLC after complete tumour resection that has activating mutations in the EGFR (deletion of exon 19 or substitution of exon 21 [L858R]) that received adjuvant treatment with osimertinib (ADAURA regimen).